Breast,
Cervical,
Gastrointestinal,
Gynecologic,
Head/Neck,
Lung,
Phase I,
Urologic
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
Not Available
Berlin, Jordan
National
Vanderbilt University
05-02-2024
Eligibility
Not Available
Not Available
Not Available
Inclusion Criteria:
Locally advanced, recurrent, or metastatic, incurable (any number of previous lines of therapy is allowed), histologically or cytologically confirmed; HR +/HER2- breast cancer; squamous cell carcinoma of the head and neck; urothelial cancer; or endometrial cancer with no more than 3 prior lines of therapy for metastatic disease
Willing and able to provide written informed consent for this study
Adults 18 years old at time of consent
Known PIK3CA mutations or amplifications as determined at a CAP/CLIA-certified or equivalently accredited diagnostic laboratory using a validated test
Measurable disease by RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy 6 months, as determined by the investigator
Adequate bone marrow, liver, and kidney function within 14 days prior to first dose of investigational product
Fasting plasma glucose = 140 mg/dL AND hemoglobin A1c (HbA1c) = 7.0%
Available archived or fresh tumor tissue sample for detection of PIK3CA mutation by central laboratory test
Exclusion Criteria:
Recent systemic anticancer treatment prior to start of treatment (EXCEPTION: Patients with breast cancer who were receiving a fulvestrant-containing regimen at the time of informed consent may remain on fulvestrant while receiving study treatment)
For non-breast cancer: prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway,
Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2 requiring antihyperglycemic medication
Known active central nervous system (CNS) metastases.
Locally advanced, recurrent, or metastatic, incurable (any number of previous lines of therapy is allowed), histologically or cytologically confirmed; HR +/HER2- breast cancer; squamous cell carcinoma of the head and neck; urothelial cancer; or endometrial cancer with no more than 3 prior lines of therapy for metastatic disease
Willing and able to provide written informed consent for this study
Adults 18 years old at time of consent
Known PIK3CA mutations or amplifications as determined at a CAP/CLIA-certified or equivalently accredited diagnostic laboratory using a validated test
Measurable disease by RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy 6 months, as determined by the investigator
Adequate bone marrow, liver, and kidney function within 14 days prior to first dose of investigational product
Fasting plasma glucose = 140 mg/dL AND hemoglobin A1c (HbA1c) = 7.0%
Available archived or fresh tumor tissue sample for detection of PIK3CA mutation by central laboratory test
Exclusion Criteria:
Recent systemic anticancer treatment prior to start of treatment (EXCEPTION: Patients with breast cancer who were receiving a fulvestrant-containing regimen at the time of informed consent may remain on fulvestrant while receiving study treatment)
For non-breast cancer: prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway,
Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2 requiring antihyperglycemic medication
Known active central nervous system (CNS) metastases.
